956-61-6

Basic information

• Product Name: 1-(4-TERT-BUTYLBENZYL)PIPERAZINE
• Synonyms: 1-(4-TERT-BUTYLBENZYL)PIPERAZINE;1-(4-tert-Butylbenzyl)piperazine 97%
• CAS NO: 956-61-6
• Molecular Formula: C₁₅H₂₄N₂
• Molecular Weight: 232.36
• Product Categories: API intermediates;Building Blocks;Heterocyclic Building Blocks;Piperazines
• Mol File: 956-61-6.mol

Chemical Properties

• Melting Point: 52-56 °C
• Boiling Point: 138-140°C 2mm
• Flash Point: 114.7 °C
• Appearance: Off-white to pale yellow/Solid
• Density: 0.974 g/cm³
• Vapor Pressure: 0.00022mmHg at 25°C
• Refractive Index: 1.523
• PKA: 9.16±0.10(Predicted)
• Sensitive: Air Sensitive
• CAS DataBase Reference: 1-(4-TERT-BUTYLBENZYL)PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-TERT-BUTYLBENZYL)PIPERAZINE(956-61-6)
• EPA Substance Registry System: 1-(4-TERT-BUTYLBENZYL)PIPERAZINE(956-61-6)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 956-61-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-TERT-BUTYLBENZYL)PIPERAZINE is used as a chemical intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs and compounds due to its unique chemical properties.
Used in Research and Development:
In the realm of research and development, 1-(4-TERT-BUTYLBENZYL)PIPERAZINE is utilized as a key component in the creation and testing of novel drug formulations, enhancing the scope of pharmaceutical innovation.
Used in Antifungal Applications:
1-(4-TERT-BUTYLBENZYL)PIPERAZINE is studied for its potential use as an antifungal agent, indicating its possible role in combating fungal infections and contributing to the field of antimicrobial chemistry.

InChI:InChI=1/C15H24N2/c1-15(2,3)14-6-4-13(5-7-14)12-17-10-8-16-9-11-17/h4-7,16H,8-12H2,1-3H3

Upstream product

• 110-85-0 piperazine 
• 19692-45-6 4-tert-butylbenzyl chloride 
• 18880-00-7 1-(bromomethyl)-4-(1,1-dimethylethyl)benzene 
• 7542-23-6 piperazine hydrochloride 

Downstream Products

• 116152-62-6 1-(4-tert-butyl-benzyl)-4-[2-(4-chloro-benzhydryloxy)-ethyl]-piperazine 
• 82-95-1 Buclifen 
• 1246343-47-4 1-(4-(tert-butyl)benzyl)-4-(2-(2-(4-(phenyldiazenyl)phenoxy)ethoxy)ethyl)piperazine 
• 1203719-16-7 1-(4-tert-butylbenzyl)-4-[6-chloro-5-(trifluoromethyl)pyridin-2-yl]piperazine 
• 1375158-65-8 1-{[1-benzyl-5-(4-methylphenyl)-1H-pyrazol-3-yl]carbonyl}-4-(4-tert-butylbenzyl)piperazine 
• 1375158-55-6 1-{[1-benzyl-3-(4-methylphenyl)-1H-pyrazol-5-yl]carbonyl}-4-(4-tert-butylbenzyl)piperazine 

Relevant articles and documents

Sequential Selective C?H and C(sp3)?+P Bond Functionalizations: An Entry to Bioactive Arylated Scaffolds

Organophosphonium salts containing C(sp3)?+P bonds are among the most utilized reagents in organic synthesis for constructing C?C double bonds. However, their use as C-selective electrophilic groups is rare. Here, we explore an efficient and general transition-metal-free method for sequential chemo- and regioselective C?H and C(sp3)?+P bond functionalizations. In the present study, C?H alkylation resulting in the synthesis of benzhydryl triarylphosphonium salts was achieved by one-pot, four-component cross-coupling reactions of simple and commercially available starting materials. The utility of the resulting phosphonium salt building blocks was demonstrated by the chemoselective post-functionalization of benzylic C(sp3)?+PPh3 groups to achieve aminations, thiolations, and arylations. In this way, benzhydrylamines, benzhydrylthioethers, and triarylmethanes, structural motifs that are present in many pharmaceuticals and agrochemicals, are readily accessed. These include the synthesis of two anticancer agents from simple materials in only two to three steps. Additionally, a protocol for late-stage functionalization of bioactive drugs has been developed using benzhydrylphosphonium salts. This new approach should provide novel transformations for application in both academic and pharmaceutical research.

Rational modifications, synthesis and biological evaluation of new potential antivirals for RSV designed to target the M2-1 protein

Respiratory syncytial virus (RSV) is the main cause of lower respiratory tract diseases in infants and young children, with potentially serious and fatal consequences associated with severe infections. Despite extensive research efforts invested in the identification of therapeutic measures, no vaccine is currently available, while treatment options are limited to ribavirin and palivizumab, which both present significant limitations. While clinical and pre-clinical candidates mainly target the viral fusion protein, the nucleocapsid protein or the viral polymerase, our focus has been the identification of new antiviral compounds targeting the viral M2-1 protein, thanks to the presence of a zinc-ejecting group in their chemical structure. Starting from an anti-RSV hit we had previously identified with an in silico structure-based approach, we have designed, synthesised and evaluated a new series of dithiocarbamate analogues, with which we have explored the antiviral activity of this scaffold. The findings presented in this work may provide the basis for the identification of a new antiviral lead to treat RSV infections.

Development of 2-amino-4-phenylthiazole analogues to disrupt myeloid differentiation factor 88 and prevent inflammatory responses in acute lung injury

Myeloid differentiation primary response protein 88 (MyD88), an essential adapter protein used by toll-like receptors (TLR), is a promising target molecule for the treatment of respiratory inflammatory diseases. Previous studies explored the activities of novel 2-amino-4-phenylthiazole analogue (6) in inflammation-induced cancer, and identified the analogue as an inhibitor of MyD88 toll/interleukin-1 receptor (TIR) homology domain dimerization. Here, we describe the synthesis of 47 new analogues by modifying different sites on this lead compound and assessed their anti-inflammatory activities in lipopolysaccharide-induced mouse primary peritoneal macrophages (MPMs). The most promising compound, 15d, was found to effectively interact with MyD88 protein and prevented formation of the MyD88 homodimeric complex. Furthermore, 15d showed in vivo anti-inflammatory activity in LPS-caused model of acute lung injury. This work provides new candidates as MyD88 inhibitors to combat inflammation diseases.

ENZYME-ACTIVATING COMPOUNDS AND COMPOSITIONS

The invention provides compounds and compositions useful for the modulation of certain enzymes. The compounds and compositions can induce of cell death, particularly cancer cell death. The invention also provides methods for the synthesis and use of the c

PROCASPASE-ACTIVATING COMPOUNDS AND COMPOSITIONS

The invention provides compounds and compositions useful for the modulation of certain enzymes. The compounds and compositions can induce of cell death, particularly cancer cell death. The invention also provides methods for the synthesis and use of the compounds and compositions, including the use of compounds and compositions in therapy for the treatment of cancer and selective induction of apoptosis in cells.

Synthesis and pharmacological evaluation of 2,4-dinitroaryldithiocarbamate derivatives as novel monoacylglycerol lipase inhibitors

Monoacylglycerol lipase (MAGL) is responsible for signal termination of 2-arachidonoylglycerol (2-AG), an endocannabinoid neurotransmitter endowed with several physiological effects. Previously, we showed that the arylthioamide scaffold represents a privileged template for designing MAGL inhibitors. A series of 37 compounds resulting from pharmacomodulations around the arylthioamide template were synthesized and tested to evaluate their inhibitory potential on MAGL activity as well as their selectivity over fatty acid amide hydrolase (FAAH), another endocannabinoid-hydrolyzing enzyme. We have identified 2,4-dinitroaryldithiocarbamate derivatives as a novel class of MAGL inhibitors. Among the synthesized compounds, we identified [2,4-dinitrophenyl-4-(4-tert- butylbenzyl)piperazine-1-carbodithioate] (CK37), as the most potent MAGL inhibitor within this series (IC50 = 154 nM). We have also identified [2,4-dinitrophenyl-4-benzhydrylpiperazine-1-carbodithioate] (CK16) as a selective MAGL inhibitor. These compounds are irreversible MAGL inhibitors that probably act by interacting with Cys208 or Cys242 and Ser122 residues of the enzyme. Moreover, CK37 is able to raise 2-arachidonoylglycerol (2-AG) levels in intact cells.

Light-responsive molecular recognition and adhesion of vesicles

Chemical eqaction Presented Supramolecular glue: The photoinduced isomerization of difunctional azobenzenes can be used to induce and reverse the molecular recognition and adhesion of bilayer vesicles made up of cyclodextrin (CD) molecules. The molecular

Design and Synthesis of Novel Insecticides Based on the Serotonergic Ligand 1-[(4-Aminophenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]piperazine(PAPP)

1-[(4-Aminophenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]piperazine (PAPP) is a 5-HT1A agonist and was reported to display high affinity for serotonin (5-HT) receptor from the parasitic nematode Haemonchus contortus. The present investigation explored the possibility of using PAPP as a lead compound of new insecticides with novel mode of action. On the basis of the PAPP scaffold, a series of 1-arylmethyl-4-[(trifluoromethyl)pyridin-2-yl]piperazine derivatives were designed, synthesized, and evaluated for biological activities against the armyworm Pseudaletia separata (Walker). Bioassays showed that most of the target compounds displayed certain growth-inhibiting activities or larvicidal activities against armyworm. The quantitative structure-activity relationship (QSAR) for growth-inhibiting activities was also analyzed and established.

INHIBITORS OF STEAROYL-COA DESATURASE

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity.